Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 325163
  • calendar_today Published On: Jan, 2023
  • file_copy Pages: 165
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Infants from 6 Weeks to 15 Months Old accounting for % of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Serotype 6B segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) include Pfizer, Minhai Bio, Kexing Bio, Cansino Bio, and Lanzhou Biological Preparations Institute, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Serotype 6B

7F Serotype

Serotype 9V

14 Serotype

Serotype 18C

Serotype 19A

19F Serotype

23F Serotype

24F Serotype

Other

Market segment by Application can be divided into

Infants from 6 Weeks to 15 Months Old

Children Aged 15 Months to 5 Years

The key market players for global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market are listed below:

Pfizer

Minhai Bio

Kexing Bio

Cansino Bio

Lanzhou Biological Preparations Institute

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), with price, sales, revenue and global market share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) from 2019 to 2022.

Chapter 3, the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13).

Chapter 13, 14, and 15, to describe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 Serotype 6B

1.2.3 7F Serotype

1.2.4 Serotype 9V

1.2.5 14 Serotype

1.2.6 Serotype 18C

1.2.7 Serotype 19A

1.2.8 19F Serotype

1.2.9 23F Serotype

1.2.10 24F Serotype

1.2.11 Other

1.3 Market Analysis by Application

1.3.1 Overview: Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application: 2017 Versus 2021 Versus 2028

1.3.2 Infants from 6 Weeks to 15 Months Old

1.3.3 Children Aged 15 Months to 5 Years

1.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size & Forecast

1.4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Value (2017 & 2021 & 2028)

1.4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume (2017-2028)

1.4.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (2017-2028)

1.5 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Capacity Analysis

1.5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Total Production Capacity (2017-2028)

1.5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers

1.6.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints

1.6.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Trends Analysis

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Pfizer Details

2.1.2 Pfizer Major Business

2.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

2.1.4 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 Minhai Bio

2.2.1 Minhai Bio Details

2.2.2 Minhai Bio Major Business

2.2.3 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

2.2.4 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 Kexing Bio

2.3.1 Kexing Bio Details

2.3.2 Kexing Bio Major Business

2.3.3 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

2.3.4 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Cansino Bio

2.4.1 Cansino Bio Details

2.4.2 Cansino Bio Major Business

2.4.3 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

2.4.4 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 Lanzhou Biological Preparations Institute

2.5.1 Lanzhou Biological Preparations Institute Details

2.5.2 Lanzhou Biological Preparations Institute Major Business

2.5.3 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

2.5.4 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Breakdown Data by Manufacturer

3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)

3.4 Market Concentration Rate

3.4.1 Top 3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturer Market Share in 2021

3.4.2 Top 6 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturer Market Share in 2021

3.5 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region

4.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Region (2017-2028)

4.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2028)

4.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028)

4.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028)

4.4 Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028)

4.5 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028)

4.6 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028)

5 Market Segment by Type

5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Type (2017-2028)

5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2028)

5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2017-2028)

6 Market Segment by Application

6.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Application (2017-2028)

6.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2028)

6.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)

7.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)

7.3 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country

7.3.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Country (2017-2028)

7.3.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)

8.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)

8.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country

8.3.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Country (2017-2028)

8.3.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)

9.2 Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)

9.3 Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region

9.3.1 Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Application

10.1 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)

10.2 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)

10.3 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country

10.3.1 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Country (2017-2028)

10.3.2 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Application

11.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2028)

11.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2028)

11.3 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country

11.3.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Key Manufacturers

12.2 Manufacturing Costs Percentage of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)

12.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Process

12.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Typical Distributors

13.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application, (USD Million), 2017 & 2021 & 2028

Table 3. Pfizer Basic Information, Manufacturing Base and Competitors

Table 4. Pfizer Major Business

Table 5. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

Table 6. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. Minhai Bio Basic Information, Manufacturing Base and Competitors

Table 8. Minhai Bio Major Business

Table 9. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

Table 10. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. Kexing Bio Basic Information, Manufacturing Base and Competitors

Table 12. Kexing Bio Major Business

Table 13. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

Table 14. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Cansino Bio Basic Information, Manufacturing Base and Competitors

Table 16. Cansino Bio Major Business

Table 17. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

Table 18. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. Lanzhou Biological Preparations Institute Basic Information, Manufacturing Base and Competitors

Table 20. Lanzhou Biological Preparations Institute Major Business

Table 21. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product and Services

Table 22. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)

Table 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 25. Market Position of Manufacturers in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Capacity by Company, (K Units): 2020 VS 2021

Table 27. Head Office and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Site of Key Manufacturer

Table 28. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) New Entrant and Capacity Expansion Plans

Table 29. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Mergers & Acquisitions in the Past Five Years

Table 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2017-2022) & (K Units)

Table 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2023-2028) & (K Units)

Table 32. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2022) & (USD Million)

Table 33. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2023-2028) & (USD Million)

Table 34. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)

Table 35. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)

Table 36. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2017-2022) & (USD Million)

Table 37. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2023-2028) & (USD Million)

Table 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2017-2022) & (US$/Unit)

Table 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2023-2028) & (US$/Unit)

Table 40. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)

Table 41. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)

Table 42. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2017-2022) & (USD Million)

Table 43. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2023-2028) & (USD Million)

Table 44. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2017-2022) & (US$/Unit)

Table 45. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2023-2028) & (US$/Unit)

Table 46. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2022) & (K Units)

Table 47. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2023-2028) & (K Units)

Table 48. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2022) & (USD Million)

Table 49. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2023-2028) & (USD Million)

Table 50. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)

Table 51. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)

Table 52. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)

Table 53. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)

Table 54. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2022) & (K Units)

Table 55. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2023-2028) & (K Units)

Table 56. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2022) & (USD Million)

Table 57. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2023-2028) & (USD Million)

Table 58. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)

Table 59. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)

Table 60. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)

Table 61. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)

Table 62. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2017-2022) & (K Units)

Table 63. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2023-2028) & (K Units)

Table 64. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2022) & (USD Million)

Table 65. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2023-2028) & (USD Million)

Table 66. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)

Table 67. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)

Table 68. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)

Table 69. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)

Table 70. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2017-2022) & (K Units)

Table 71. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2023-2028) & (K Units)

Table 72. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2017-2022) & (USD Million)

Table 73. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2023-2028) & (USD Million)

Table 74. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)

Table 75. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)

Table 76. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)

Table 77. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)

Table 78. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2017-2022) & (K Units)

Table 79. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2023-2028) & (K Units)

Table 80. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2017-2022) & (USD Million)

Table 81. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2023-2028) & (USD Million)

Table 82. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2017-2022) & (K Units)

Table 83. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2023-2028) & (K Units)

Table 84. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2017-2022) & (K Units)

Table 85. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2023-2028) & (K Units)

Table 86. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Raw Material

Table 87. Key Manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Raw Materials

Table 88. Direct Channel Pros & Cons

Table 89. Indirect Channel Pros & Cons

Table 90. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Typical Distributors

Table 91. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Typical Customers

List of Figures

Figure 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Picture

Figure 2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type in 2021

Figure 3. Serotype 6B

Figure 4. 7F Serotype

Figure 5. Serotype 9V

Figure 6. 14 Serotype

Figure 7. Serotype 18C

Figure 8. Serotype 19A

Figure 9. 19F Serotype

Figure 10. 23F Serotype

Figure 11. 24F Serotype

Figure 12. Other

Figure 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application in 2021

Figure 14. Infants from 6 Weeks to 15 Months Old

Figure 15. Children Aged 15 Months to 5 Years

Figure 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028

Figure 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Forecast (2017-2028) & (USD Million)

Figure 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (2017-2028) & (K Units)

Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (2017-2028) & (US$/Unit)

Figure 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Capacity (2017-2028) & (K Units)

Figure 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Production Capacity by Geographic Region: 2022 VS 2028

Figure 22. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers

Figure 23. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints

Figure 24. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Trends

Figure 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Manufacturer in 2021

Figure 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Manufacturer in 2021

Figure 27. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 28. Top 3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturer (Revenue) Market Share in 2021

Figure 29. Top 6 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturer (Revenue) Market Share in 2021

Figure 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2017-2028)

Figure 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2017-2028)

Figure 32. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (USD Million)

Figure 33. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (USD Million)

Figure 34. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (USD Million)

Figure 35. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (USD Million)

Figure 36. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (2017-2028) & (USD Million)

Figure 37. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)

Figure 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2017-2028)

Figure 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2017-2028) & (US$/Unit)

Figure 40. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)

Figure 41. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2017-2028)

Figure 42. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2017-2028) & (US$/Unit)

Figure 43. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)

Figure 44. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)

Figure 45. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2017-2028)

Figure 46. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2017-2028)

Figure 47. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)

Figure 51. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)

Figure 52. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2017-2028)

Figure 53. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2017-2028)

Figure 54. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. United Kingdom 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2017-2028)

Figure 60. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)

Figure 61. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2017-2028)

Figure 62. Asia-Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2017-2028)

Figure 63. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)

Figure 70. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)

Figure 71. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2017-2028)

Figure 72. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2017-2028)

Figure 73. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Argentina 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2017-2028)

Figure 76. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2017-2028)

Figure 77. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2017-2028)

Figure 78. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2017-2028)

Figure 79. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Egypt 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Saudi Arabia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. South Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in 2021

Figure 84. Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)

Figure 85. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industrial Chain

Figure 86. Sales Channel: Direct Channel vs Indirect Channel

Figure 87. Methodology

Figure 88. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz